Health care industry lobbying spending reached unprecedented levels in Q1 2026 as major pharmaceutical companies, insurers, and trade groups responded to intensifying Trump administration scrutiny ahead of midterm elections. AHIP spent a record $5.3 million, PhRMA spent $12.2 million, and companies including Eli Lilly, Gilead, and Regeneron all reported their highest quarterly lobbying expenditures on record. The surge follows President Trump's January 2026 directive ordering Congress to codify drug pricing deals, send health insurance money directly to Americans, and require more price transparency from insurers, while Health Secretary Robert F. Kennedy Jr. leads the Make America Healthy Again movement questioning drug and food safety. The lobbying blitz comes as Trump's One Big Beautiful Bill Act included nearly $1 trillion in Medicaid cuts and enhanced Obamacare subsidies expired, prompting health care firms to hire top K Street lobbying shops to protect their business interests.
Story comments
Loading comments…